Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Primary Epstein–Barr virus infection diffusing F18-fluorodeoxyglucose-positron emission tomography/computed tomography response monitoring of Hodgkin’s disease: a case report

Journal of Medical Case Reports20148:212

https://doi.org/10.1186/1752-1947-8-212

Received: 15 January 2014

Accepted: 21 April 2014

Published: 20 June 2014

Abstract

Introduction

Hodgkin’s disease is highly curable by radiotherapy and/or chemotherapy, but refractory disease or early relapses are rarely cured by conventional salvage therapy.

Case presentation

We report a case of a 20-year-old Caucasian man, with a biopsy-proven intrapulmonary relapse of Hodgkin’s disease, for whom salvage chemotherapy was administered. During salvage chemotherapy intense increased F18-fluorodeoxyglucose uptake was noticed in multiple lymph nodes and diffuse increased splenic uptake, suggesting chemotherapy-refractory disease. However, additional information obtained from the patient revealed he recently had met his first girlfriend. An asymptomatic primary Epstein–Barr virus infection was considered proven.

Conclusions

Interim F18-fluorodeoxyglucose-positron emission tomography/computed tomography is a strong prognostic factor for advanced Hodgkin’s and may better identify those patients needing intensified chemotherapy. Related to the nonspecificity of F18-fluorodeoxyglucose, clinical awareness of the potential interference of intercurrent asymptomatic viral infections with treatment and remission status monitoring continues to be important in the interpretation of equivocal medical imaging results.

Keywords

Autologous stem-cell transplantation (ASCT)Epstein–Barr virus (EBV)F18-FDG positron emission tomography/computed tomography (PET/CT)Hodgkin’s disease (HD)

Introduction

Hodgkin’s disease (HD) is highly curable by radiotherapy and/or chemotherapy, but refractory disease or early relapses are rarely cured by conventional salvage therapy [1].

Additional high-dose chemotherapy (HDCT), such as carmustine, etoposide, cytarabine and melphalan (BEAM) in combination with autologous stem-cell transplantation (ASCT), is used to salvage and cure these patients. Since only chemosensitive patients with relapsed HD benefit from ablative therapy and ASCT, adequate response to salvage chemotherapy, assessed by serial positron emission tomography/computed tomography (PET/CT) is pivotal to progress to HDCT and ASCT. We report a case of a young man with early intrapulmonary relapse of HD in whom during salvage chemotherapy on interim PET/CT generalized PET-positive lymphadenopathy was observed, caused by a primary Epstein–Barr virus (EBV) infection and not by progressive disease.

Case presentation

A 20-year-old Caucasian man was diagnosed with nodular sclerosing HD stage III-SA with an International Prognostic Score (IPS) of 2 with cervical, supraclavicular, axillary retroperitoneal lymph node localizations, with a bulky mediastinal mass and a splenic nodule on PET/CT with F18-fluorodeoxyglucose (FDG). A response evaluation 8 months later after six cycles of Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine with F18-FDG-PET/CT showed a major, both morphologic and metabolic, partial response with minimal focal metabolic activity in his left hilar region for which additional infranodal radiotherapy (in total 15×2Gy) on the mediastinal mass was given. Four months later, after radiotherapy the response evaluation by PET/CT revealed three metabolic active extranodal lesions in his left lung. Relapse of HD was histologically proven using CT-guided biopsy (Figure 1).
Figure 1

Interim F 18 -fluorodeoxyglucose-positron emission tomography/computed tomography revealed biopsy/histology-proven intrapulmonary relapse of Hodgkin’s disease after six cycles of Adriamycin ® (doxorubicin), bleomycin, vinblastine, dacarbazine and infranodal radiotherapy of a mediastinal mass. The left image is the total body maximum intensity projection image. The coinciding transverse positron emission tomography and computed tomography slices show the caudal lesion of a total of three lesions in the left lung (black arrows).

Salvage chemotherapy consisted of two cycles of cisplatinum, cytarabine, and dexamethasone (DHAP) and one cycle of etoposide, ifosfamide, and methotrexate (VIM), followed by ASCT with BEAM conditioning was proposed.

Response evaluation using interim F18-FDG-PET/CT, after one cycle of DHAP and VIM chemotherapy showed a partial metabolic response in his lung nodes, his maximum standardized uptake value (SUVmax) decreased from 12 and 15 in left upper and lower lobe respectively, to SUVmax 6 and 8.

New symmetrical intense FDG uptake in his adenoids (SUVmax 24), and in multiple bilateral cervical (SUVmax 10), axillary lymph nodes and in a lymph node within the high-right para-aorta (SUVmax 6.5) and a lower-right mesenteric lymph node, with furthermore diffuse increased splenic F18-FDG uptake (SUVmax 6) suggested rapidly progressive disease (Figure 2). However, the coincidence of both an extensive nodular relapse with a partial response of the extranodal lung lesions was regarded unlikely. Additional information obtained from the patient revealed he had recently met his first girlfriend. Additional virus serology tests showed EBV-specific immunoglobulin M antibodies and EBV deoxyribonucleic acid (DNA) copies in peripheral blood.
Figure 2

The second interim F 18 -fluorodeoxyglucose-positron emission tomography/computed tomography after cycles of cisplatinum, cytarabine, and dexamethasone, and etoposide, ifosfamide and methotrexate, showing decreased metabolic activity in the three lesions in the left lung indicating partial response. However, new pathological increased fluorodeoxyglucose uptake is seen in multiple bilateral cervical plus axillary lymph nodes and furthermore increased metabolic activity in the spleen and in a lymph node within the high-right para-aortal and in a lower-right mesenteric lymph node (black arrows). Virus serology was positive for Epstein–Barr virus.

We hypothesized that the asymptomatic primary EBV infection was responsible for the extensive PET-positive lymphadenopathy with a concurrent partial response of HD after DHAP-VIM chemotherapy. After disappearance of EBV DNA copies the second DHAP chemotherapy cycle was given without flare-up of the infection.An interim PET/CT, 2 months after completion of the last DHAP chemotherapy and with absence of EBV DNA in peripheral blood showed metabolic activity in only one of the three lung lesions and only marginal increased activity in a (probably reactive) small mediastinal pre-aortal lymph node (Figure 3). After extensive discussion, he progressed to ASCT and subsequent BEAM conditioning chemotherapy. In the event of extrapulmonary disease progression, he will be considered for treatment with brentuximab vedotin (an antibody-drug conjugate directed to the protein CD30).
Figure 3

F 18 -fluorodeoxyglucose-positron emission tomography/computed tomography after completion of chemotherapy with cisplatinum, cytarabine, and dexamethasone-etoposide, ifosfamide, and methotrexate cisplatinum, cytarabine, and dexamethasone and absence of Epstein–Barr virus deoxyribonucleic acid in peripheral blood. Only the most apical of the three lesions in the left lung is still metabolically active. Minor activity is seen in a small pre-aortal lymph node (thick arrows).

Discussion

EBV is a widely distributed gammaherpesvirus; approximately 90% of adults throughout the world are EBV-positive. Exposure to EBV predominantly occurs in early adulthood. EBV may cause a number of clinical syndromes, including acute mononucleosis and has been associated with a variety of malignancies, including B-cell and T-cell lymphoma [2]. Acute primary infection with EBV is mostly characterized by transient fever, lymphadenopathy and may cause a transient hepatosplenomegaly. The severity and presentation may range from an asymptomatic infection to a serious life-threatening version of mononucleosis with associated liver damage or even rupture of the spleen [3]. Our patient elegantly illustrates that a subclinical primary EBV infection may intervene with both the treatment of HD and remission status judgment. Since PET/CT is rarely used as a diagnostic tool to detect a primary EBV infection in daily clinical practice, only a few case reports have been published. These cases demonstrated that F18-FDG uptake can be intense in lymph nodes and spleen and may mimic lymphoma [46]. The choice to opt for interim F18-FDG PET/CT scans was not only based on the combination of the young age of our patient and the prognostic implications of his relapse. Interim PET is the strongest prognostic factor that is reported for advanced HD, and overshadows the impact of the IPS [7, 8]. This case report also supports that better risk stratification, based on early interim (PET) evaluation, may better identify those patients needing intensified chemotherapy. Furthermore, in larger studies the intensification of chemotherapy and the optimal use of PET at the end of chemotherapy have already minimized the use of radiotherapy in advanced disease, thus reducing the risk of long-term complications [9].

Conclusions

We describe a case with pulmonary relapse of HD, in whom an asymptomatic primary EBV infection was diagnosed during salvage chemotherapy on suggestion of the interim PET/CT. Clinical awareness of intercurrent asymptomatic viral infections, potentially interfering with treatment and remission status monitoring remain important in the interpretation of equivocal medical imaging results.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the Editor-in-Chief of this journal.

Abbreviations

ASCT: 

Autologous stem-cell transplantation

BEAM: 

Carmustine, etoposide, cytarabine and melphalan

CT: 

Computed tomography

DHAP: 

Cisplatinum, cytarabine and dexamethasone

EBV: 

Epstein–Barr virus

FDG: 

F18-fluorodeoxyglucose

HD: 

Hodgkin’s disease

HDCT: 

High-dose chemotherapy

IPS: 

International Prognostic Score

PET: 

Positron emission tomography

SUVmax: 

Maximum standardized uptake value

VIM: 

Etoposide, ifosfamide and methotrexate.

Declarations

Authors’ Affiliations

(1)
Department of Nuclear Medicine, Medical Center Leeuwarden
(2)
Department of Haematology, Medical Center Leeuwarden

References

  1. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992, 10: 210-218.PubMedGoogle Scholar
  2. Klutts JS, Ford BA, Perez NR, Gronowski AM: Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009, 47: 3204-3210.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Okano M, Gross TG: Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection. Am J Med Sci. 2012, 343: 483-489.View ArticlePubMedGoogle Scholar
  4. Thomas DL, Syrbu S, Graham MM: Epstein-Barr virus mimicking lymphoma on FDG-PET/CT. Clin Nucl Med. 2009, 34: 891-893.View ArticlePubMedGoogle Scholar
  5. Lustberg MB, Aras O, Meisenberg BR: FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol. 2008, 81: 154-156.View ArticlePubMedGoogle Scholar
  6. Tomas MB, Tronco GG, Karayalcin G, Palestro CJ: 22. FDG Uptake in Infectious Mononucleosis. Clin Positron Imaging. 2000, 3: 176-View ArticlePubMedGoogle Scholar
  7. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A: Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007, 25: 3746-3752.View ArticlePubMedGoogle Scholar
  8. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A: Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014, 55 (1): 31-37.View ArticlePubMedGoogle Scholar
  9. Vassilakopoulos TP, Angelopoulou MK: Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol. 2013, 50: 4-14.View ArticlePubMedGoogle Scholar

Copyright

© Balink and Hoogendoorn; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement